<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: K-<z:mp ids='MP_0011356'>RAS</z:mp> mutation poses a particularly difficult problem for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Activating mutations in K-<z:mp ids='MP_0011356'>RAS</z:mp> are common in <z:e sem="disease" ids="C0684249,C0242379" disease_type="Neoplastic Process" abbrv="">cancers of the lung</z:e>, pancreas, and colon and are associated with poor response to therapy </plain></SENT>
<SENT sid="2" pm="."><plain>As such, targeted therapies that abrogate K-<z:mp ids='MP_0011356'>RAS</z:mp>-induced oncogenicity would be of tremendous value </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We searched for small molecule kinase inhibitors that preferentially affect the growth of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells expressing mutant K-<z:mp ids='MP_0011356'>RAS</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>The mechanism of action of one inhibitor was explored using chemical and genetic approaches </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: We identified BAY61-3606 as an inhibitor of proliferation in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells expressing mutant forms of K-<z:mp ids='MP_0011356'>RAS</z:mp>, but not in isogenic cells expressing <z:mp ids='MP_0002169'>wild-type</z:mp> K-<z:mp ids='MP_0011356'>RAS</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>In addition to its anti-proliferative effects in mutant cells, BAY61-3606 exhibited a distinct biological property in <z:mp ids='MP_0002169'>wild-type</z:mp> cells in that it conferred sensitivity to inhibition of RAF </plain></SENT>
<SENT sid="7" pm="."><plain>In this context, BAY61-3606 acted by inhibiting MAP4K2 (GCK), which normally activates NFκβ signaling in <z:mp ids='MP_0002169'>wild-type</z:mp> cells in response to inhibition of RAF </plain></SENT>
<SENT sid="8" pm="."><plain>As a result of MAP4K2 inhibition, <z:mp ids='MP_0002169'>wild-type</z:mp> cells became sensitive to AZ-628, a RAF inhibitor, when also treated with BAY61-3606 </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These studies indicate that BAY61-3606 exerts distinct biological activities in different genetic contexts </plain></SENT>
</text></document>